Evaluating a new treatment for inflammatory bowel diseases using human intestinal models
Official title: Evaluation of an Anti-TREM-1 Treatment on an ex Vivo Human Intestinal Model
Run by Inotrem · NCT06580418 · Data updated 2026-11-12
This study is testing a new treatment for ulcerative colitis and Crohn's disease to see if it can help manage these conditions better.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Inotrem Industry-sponsored |
| Locations | 1 site (Milan) |
| Status | Recruiting |
| Started | January 31, 2023 |
| Main results expected | March 31, 2025 |
| Study ends | March 31, 2025 |
| Registry record updated | February 27, 2025 |
| Trial ID | NCT06580418 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 60 with active ulcerative colitis or Crohn's disease.
✕Probably not a fit
Patients in remission from ulcerative colitis or Crohn's disease will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on patients with ulcerative colitis and Crohn's disease who are under endoscopic surveillance to monitor their disease activity. The main goal is to assess the therapeutic potential of TREM-1 in treating inflammatory bowel diseases. Participants will undergo additional biopsies and blood sample collection to gather data on the treatment's effectiveness. The study aims to provide insights into how TREM-1 can influence disease management in these patients.
Why it matters
Potential benefit: If successful, this treatment could offer a new therapeutic option for patients suffering from inflammatory bowel diseases.
How similar studies have gone: While this approach is novel, similar studies targeting inflammatory bowel diseases have shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients between 18 and 60 years * Signed informed consent * Ulcerative colitis (UC) patients with active disease * Crohn's disease (CD) patients with active disease Exclusion Criteria: * UC or CD patients in remission * Patients between 18 and 60 years without informed consent
Where it's running
-
IRCCS San Raffaele
Milan, Italy Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Long-Term Guselkumab Use in Adults with Inflammatory Bowel Disease
This study looks at how long adults with Crohn's disease or ulcerative colitis stay on guselkumab in real-world care.
-
Intestinal ultrasound-guided management for inflammatory bowel disease
This study tests if adding point-of-care intestinal ultrasound at every visit changes treatment decisions for adults with Crohn’s disease or ulcerative colitis undergoing disease assessment.
-
Resting energy use in kids with inflammatory bowel disease
This multicenter study will test the resting energy expenditure of children aged 6–17 with new IBD diagnoses to see how it relates to disease activity and treatment.
-
Active video education by disease subtype to improve bowel prep before colonoscopy
We’re testing whether adding subtype-specific video education to standard prep improves bowel cleanliness in adults with IBD undergoing colonoscopy.
-
Intestinal ultrasound to predict relapse in Crohn's disease patients in deep remission.
This project will try to see if a noninvasive transabdominal ultrasound can predict relapses in adults with Crohn's disease who are currently in deep remission.
-
Ath-063: Testing a new treatment for moderately to severely active ulcerative colitis in patients who have tried other biologics
This study tests ATH-063 to see if it helps people with moderate to severe ulcerative colitis who did not respond to or relapsed after prior biologic therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.